Abstract
The implications of COVID-19 are wide-ranging for specialties, like Rheumatology, where immunomodulatory therapies are prescribed, and there has been much trepidation amongst many healthcare professionals regarding the best course of management during this time. This pandemic has also left many national policy-makers perplexed due to our limited knowledge of the effects of COVID-19 in patients with rheumatic disease. Such limitations have resulted in variable evolving guidance amongst Rheumatologists around the globe.
In this issue
COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?
